Omeprazole magnesium
Based on 10 publication(s) in Google Scholar
Omeprazole (H 16868) magnesium is an orally active H+,K+-ATPase inhibitor and a proton pump inhibitor. Omeprazole magnesium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole magnesium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole magnesium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole magnesium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole magnesium aslo has neuroprotective and antibacterial effects.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 95382-33-5
- Fòrmula: C34H36MgN6O6S2
- Peso molecular:713.12
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Omeprazole magnesium
More- Cell Metab. 2024 Jun 18:S1550-4131(24)00189-X. [Abstract]
- Cell Host Microbe. 2025 Oct 8;33(10):1715-1730.e5. [Abstract]
- Nat Commun. 2023 Jul 14;14(1):4217. [Abstract]
- Adv Sci (Weinh). 2023 Jun;10(17):e2207017. [Abstract]
- Int J Antimicrob Agents. 2025 Oct 8;66(6):107639. [Abstract]
- Sci Rep. 2026 Mar 20;16(1):14300. [Abstract]
- J Pharm Biomed Anal. 2025 Aug 22:267:117128. [Abstract]
- Tissue Cell. 2026 Apr 22:102:103551. [Abstract]
- Br J Clin Pharmacol. 2026 May 31. [Abstract]
- Xenobiotica. 2024 Oct;54(10):847-854. [Abstract]
Ver todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
Omeprazole magnesium (15 min) competitively inhibits CYP2C9 activity in pooled human liver microsomes with a Ki of 16.4 μM[1].
Omeprazole magnesium (20 min) competitively inhibits CYP2C19 activity in pooled human liver microsomes with a Ki of 2.4-6.2 μM μM[1].
Omeprazole magnesium (15 min) does not significantly inhibit CYP2D6 activity in pooled human liver microsomes, with an IC50 >200 μM[1].
Omeprazole magnesium (15 min) competitively inhibits CYP3A4 activity in pooled human liver microsomes with a Ki of 41.9 μM[1].
Omeprazole magnesium (0-200 μg/mL; 4 days) inhibits proliferation of MiaPaCa-2, ASPC-1, Panc-1, Colo357, PancTu-1, and Panc89 human pancreatic cancer cell lines in a dose-dependent manner with IC50 values ranging from 9.1 to 42.4 μg/mL[2].
Omeprazole magnesium (80 μg/mL; 30 min-24 ) does not cause consistent intralysosomal pH changes in MiaPaCa-2 and ASPC-1 human pancreatic cancer cell lines, but increases acidity in ASPC-1 cells and decreases acidity in MiaPaCa-2 cells after 24 hours of incubation at 80 μg/mL[2].
Omeprazole magnesium (80-160 μg/mL; 24 h) induces accumulation of early autophagic markers (phagophores and autophagosomes) in MiaPaCa-2 and ASPC-1 human pancreatic cancer cell lines, and induces apoptosis in ASPC-1 cells[2].
Omeprazole magnesium (80 μg/mL; 24 h) accumulates intracellularly in MiaPaCa-2 and ASPC-1 human pancreatic cancer cell lines, and induces changes in fatty acid and phospholipid metabolism[2].
Omeprazole magnesium (80 μg/mL; 24 h) alters the distribution of lysosomal markers and reduces Golgi complex marker expression in MiaPaCa-2 human pancreatic cancer cells, indicating disruption of the lysosomal transport pathway without accumulating in lysosomes or the Golgi complex[2].
Omeprazole magnesium (40-160 μg/mL; 24 h) induces autophagy in a dose-dependent manner with elevated LC3-I and LC3-II levels, and impairs autophagosome turnover in MiaPaCa-2 and ASPC-1 human pancreatic cancer cell lines[2].
Omeprazole magnesium (80 μg/mL; 6-24 h) alters gene expression in ASPC-1 and MiaPaCa-2 human pancreatic cancer cell lines, downregulating bad and survivin and upregulating mdr-1 in ASPC-1 cells[2].
Omeprazole magnesium (80 μg/mL; 24 h) activates autophagy via upregulation of Atg12 in MiaPaCa-2 and ASPC-1 human pancreatic cancer cell lines, and upregulates pro-apoptotic Puma in ASPC-1 cells[2].
Omeprazole magnesium generate sulfone, sulfite
and hydroxy-omeprazole, compounds that can generate more oxidative damage [3].
Omeprazole magnesium exerts toxicogenic effects in Allium cepa plant cells, as well as Saccharomyces cerevisiae and murine Sarcoma 180 cells[3].
Omeprazole magnesium (200-300 mg/L) results in a
dose-dependent inhibition of E.faecalis at time zero[6].
Omeprazole magnesium (200 mg/L) inhibits S. aureus at both time zero and 2 h[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MiaPaCa-2, ASPC-1, Panc-1, Colo357, PancTu-1, Panc89
-
Concentration:0-200 μg/mL
-
Incubation Time:4 days
-
Result:Inhibited cell proliferation in a dose-dependent manner, with IC50 values of 42.4 μg/mL (MiaPaCa-2), 11.2 μg/mL (ASPC-1), 31.8 μg/mL (Panc-1), 26.4 μg/mL (Colo357), 20.7 μg/mL (PancTu-1), and 9.1 μg/mL (Panc89).
Showed a mild growth-stimulatory hormetic effect in some cell lines at low concentrations.
Mitigated the hormetic growth stimulation induced by low-dose 5-fluorouracil (HY-90006) in ASPC-1, Panc-1, and PancTu-1 cells.
Showed additive effects with low-dose 5-fluorouracil in MiaPaCa-2 cells.
Showed antagonistic effects with low-dose 5-fluorouracil in Panc89 cells.
Showed additive or antagonistic interactions with gemcitabine.
-
Cell Line:40 μg/mL, 80 μg/mL, 160 μg/mL
-
Concentration:24 h
-
Incubation Time:4 days
-
Result:Caused a dose-dependent marked elevation of LC3-I and LC3-II fractions in both cell lines.
-
Cell Line:ASPC-1, MiaPaCa-2
-
Concentration:6 h, 12 h, 18 h, 24 h
-
Incubation Time:4 days
-
Result:Significantly downregulated pro-apoptotic bad mRNA in ASPC-1 cells after 24 hours.
Significantly downregulated pro-survival survivin mRNA in ASPC-1 cells after 24 hours.
Significantly upregulated mdr-1 mRNA in ASPC-1 cells after 24 hours.
Did not significantly alter mdr-1 mRNA expression in MiaPaCa-2 cells.
Omeprazole magnesium prevents Oxaliplatin (HY-17371)-induced peripheral neuropathy in Rattus norvegicus[5].
Omeprazole magnesium reduces the levels of the inflammatory cytokines, tumor necrosis factor-α, interleukin-1β, and interleukin-6, in sciatic nerve-ligated mice[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, 9 weeks old at study initiation)[4]
-
Dosage:20 mg/kg
-
Administration:s.c.; daily; 12 weeks; 24 weeks
-
Result:Decreased villous length and mucosa-to-serosa amplification ratio in duodenum, jejunum, and ileum compared to controls.
Increased duodenal crypt depth and width compared to controls.
Reduced the number of secretory granules per Paneth cell in duodenum, jejunum, and ileum after 24 weeks of treatment compared to controls.
Increased CD3+ intraepithelial lymphocytes and CD8+ intraepithelial lymphocytes compared to controls.
Reduced plasma Mg2+ levels to 0.64 mM after 12 weeks and 0.57 mM after 24 weeks compared to control level of 1.07 mmol/L.
Reduced urinary Mg2+ excretion compared to controls.
Increased fecal Mg2+ excretion after 24 weeks of treatment compared to controls.
Reduced bone and muscle Mg2+ content.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 95382-33-5
-
Peso molecular 713.12
-
Fòrmula C34H36MgN6O6S2
-
SMILES
COC1=CC=C2[N]3=C([N-]C2=C1)[S](CC(N=CC(C)=C4OC)=C4C)=[O][Mg+2]35[N](C6=CC=C7OC)=C([N-]C6=C7)[S](CC(N=CC(C)=C8OC)=C8C)=[O]5
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer. [Abstract]2024 Jun 18:S1550-4131(24)00189-X. PMID: 38897198 -
Cell Host Microbe
2025 Oct 8;33(10):1715-1730.e5. PMID: 40961933 -
Nat Commun
2023 Jul 14;14(1):4217. PMID: 37452028 -
Adv Sci (Weinh)
CCR7 Mediated Mimetic Dendritic Cell Vaccine Homing in Lymph Node for Head and Neck Squamous Cell Carcinoma Therapy. [Abstract]2023 Jun;10(17):e2207017. PMID: 37092579 -
Int J Antimicrob Agents
Expanded applications of omeprazole: Synergistic reversal of colistin resistance in Acinetobacter baumannii. [Abstract]2025 Oct 8;66(6):107639. PMID: 41072861 -
Sci Rep
2026 Mar 20;16(1):14300. PMID: 41862552 -
J Pharm Biomed Anal
Comprehensive identification and characterization of in vitro and in vivo metabolites of the novel GLP-1 receptor agonist danuglipron using UHPLC-QToF-MS/MS. [Abstract]2025 Aug 22:267:117128. PMID: 40865303 -
Tissue Cell
Vitamin D3 in synergy with triple therapy to eradicate Helicobacter pylori infection in mice via the c-Raf/MEK/ERK pathway. [Abstract]2026 Apr 22:102:103551. PMID: 42033901 -
Br J Clin Pharmacol
Evaluation of a pantoprazole and 4-desmethylpantoprazole-sulfate metabolic ratio as a novel CYP2C19 phenotyping method. [Abstract]2026 May 31. PMID: 42219154 -
Xenobiotica
Notable drug-drug interaction between omeprazole and voriconazole in CYP2C19 *1 and *2 (rs4244285, 681G>A) alleles in vitro. [Abstract]2024 Oct;54(10):847-854. PMID: 39445918
Pureza y Documentación
Referencias
[1]. Li XQ, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821-827. [Content Brief]
[2]. Udelnow A, et al. Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells. PLoS One. 2011;6(5):e20143. [Content Brief]
[3]. da Mata AMOF, et al. Evaluation of mutagenesis, necrosis and apoptosis induced by omeprazole in stomach cells of patients with gastritis. Cancer Cell Int. 2022;22(1):154. Published 2022 Apr 18. [Content Brief]
[4]. Chamniansawat S, et al. Ultrastructural intestinal mucosa change after prolonged inhibition of gastric acid secretion by omeprazole in male rats. Anat Sci Int. 2021;96(1):142-156. [Content Brief]
[5]. Mori Y, et al. Class effects of proton pump inhibitors in preventing oxaliplatin-induced peripheral neurotoxicity. J Pharmacol Sci. 2025;159(4):279-282. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Omeprazole magnesium Related Classifications
HY-109546 Related Classifications
Powered by Bioz